Category Archives: Regenerative Medicine

Role of Stem Cells on Cognitive Dysfunction after Cancer Therapy
You #39;d think getting a cancer diagnosis and the subsequent chemo and/or radiation therapy is traumatic enough. But many people receiving cancer therapy also s...

By: California Institute for Regenerative Medicine

Read the original:
Role of Stem Cells on Cognitive Dysfunction after Cancer Therapy - Video

In this weeks TechKnow, we meet baby Grace, who is part of an innovative FDA study that uses her umbilical cord bloodbanked after her birthto help treat hydrocephalus, a condition that causes swelling of the brain. Its part of a movement towards regenerative medicine that sounds like sci-fi but is grounded in decades of research.

I personally believe that cell therapy and regenerative medicine are going to be the next big advance in medicine, says Dr. Joanne Kurtzberg, head of Duke Universitys Pediatric Blood Program. Cells like [those found in] cord blood are going to drive that pull. I really think we are at the tip of the iceberg.

Dr. K, as shes known at Duke, walked us through what you need to know about harvesting stem cells from cord blood, and how one typeprogenitor cellscould truly revolutionize treatments.

There are about 253 million cells in the cord blood that was frozen after Graces birth.

The blood bag is taken from where its been stored in a liquid nitrogen freezer, gently defrosted in a water bath, and meticulously prepared at the lab during a 90-minute process.

We typically get 3 to 5 ounces of blood, Kurtzberg explains. "Only a small fraction of those cells are the important cells for the therapy.

There are probably only 20 real stem cells in the whole cord blood collection, and we dont know what they look likethey are hiding out. We know that they are in there, and we know that when we get the whole unit back, they will be contained in the other cells,but we dont know how to pull them out and find them and just use them alone for therapy.

Besides those 20 or so stem cells, there are probably hundreds of thousands of what we call progenitor cells. They are cells that have already made the decision to be one type of cell, be it a liver cell, or heart cell, or muscle cell, or an eyelid cell, or a blood cell, or a lung cell or a brain cell. When we infuse progenitor cells back into the patient, they go back to the damaged organs and do the real job of helping repair those organs.

Watch TechKnow Saturdays at 7:30 p.m. ET/4:30 p.m. PT.

Read more:
Dr. Joanne Kurtzberg: Regenerative medicine next big advance

San Diego, CA (PRWEB) February 18, 2015

San Diego's foremost regenerative medical group, National Institutes for Regenerative Medicine (National IRM) launches complimentary seminars to educate Southern California residents on the revolution of stem cell therapy as an alternative solution for patient's suffering from the most common knee, hip, back or neck pain as well as other arthritic and degenerative conditions. National IRM is an affiliate of the Cell Surgical Network, a collaborative research partner helping to rapidly advance the field and educate the public about Regenerative Medicine.

Regenerative Medicine, commonly referred to as Stem Cell Therapy is a ground-breaking procedure that heals the most common joint and osteoarthritis conditions with human tissue. In a single day, National IRM uses a simple injection of a patient's own Adipose (Adult) stem cells to help regenerate and rebuild almost any joint in the body, increase mobility and allow patients to continue an active, virtually pain-free lifestyle. Initially available only overseas to NFL and NBA athletes and celebrities, National IRM pioneers the most advanced, minimally invasive technology in Southern California's own backyard.

"As we age, the ability to maintain a healthy and active lifestyle is critical for longevity," states Board Certified Plastic Surgeon and National IRM's Chief Medical Officer, Dr. Jon Wilensky. "With age, however a variety of factors inhibit our ability to continue active lifestyles, often in the form of painful, joint related conditions. We're taking a proactive approach to life by offering individuals access to the most advanced Adipose Stem Cell Therapy as an effective alternative to a long and painful recovery typically associated with surgery."

In an effort to reach Southern California residents seeking a solution to chronic, arthritic pain, Dr. Jon Wilensky and The National IRM partnered with Omni La Costa Resort and Spa to offer monthly, complimentary seminars to educate the public on the revolution of stem cell therapy and how this state-of-the-art treatment can help improve longevity and quality of life for candidates suffering from common, joint related conditions, or who may be considering elective surgery due to injury or arthritis.

The next Stem Cell Therapy Seminar will take place Thursday, February 26th from 6:30pm-8:30pm. Registration for the seminar is free and available on National IRM's Seminar website http://explore.nationalirm.com/seminar/

About National IRM National Institutes for Regenerative Medicine (National IRM) is the foremost regenerative medical group in San Diego, CA with a mission to enhance lives by providing the latest advancements in adult stem cell therapy. Through an effective, minimally invasive procedure, National IRM uses uses a patient's own cells, Adipose (Adult) stem cells to help repair some of the world's most common tendon, ligament and bone injuries as well as arthritis. Boasting a team of board-certified specialists, National IRM delivers a multi-disciplinary approach to regenerative medicine, customizing stem cell therapy programs specific to patient's condition to help regenerate and rebuild almost any joint, increase mobility and allow patients to continue an active, virtually pain-free lifestyle.

National IRM is an institutional Review Board (IRB) Approved Research Network. National IRM affiliated with the Cell Surgical Network for the investigational use of SVF for degenerative condition

Here is the original post:
San Diego's Foremost Regenerative Medical Group, National IRM Launches Complimentary, Educational Seminars on Stem ...

MIAMI (PRWEB) February 17, 2015

Regenestem Network, a subsidiary of the Global Stem Cells Group, announced plans to join Charles Mahl, M.D. to open a Regenestem Health Clinic in the historic Westin Colonnade in Coral Gables, Florida. The state-of-the-art clinic will serve as the flagship center for the Regenestem Network and U.S. headquarters for stem cell training courses and patient treatments.

Mahl, a specialist in regenerative medicine, preventive aging medicine and pain therapy, is a member of the Global Stem Cells Group Advisory Board. His recent plans to open a clinic in the spectacular landmark hotel in central Miami lead Mahl to invite Global Stem Cells Group co-founder and Regenestem CEO Ricardo DeCubas to collaborate.

The Westin Colonnade clinic will offer pain, anti-aging and aesthetic regenerative medicine treatments and therapies.

The Regenestem Network is a global family of premier regenerative medicine providers all sharing the same missionto bring the latest in stem cell medicine to patients worldwide. The Regenestem Network is comprised of physicians, medical professionals, researchers, teachers and regenerative medicine product development specialists.

Regenestems commitment to helping improve the quality of life for patients through stem cell therapies makes it a model I wanted to incorporate into the clinic, Mahl says. This collaborative framework will allow us to offer patients promising new stem cell therapies and treatments.

The clinics location within the historic Coral Gables Westin Colonnade in central Miami will welcome patients from across the U.S., Canada, and worldwide. Located just five minutes from the University of Miami, the iconic neoclassical hotel built in the early 20th century that originally served as the offices for Coral Gables intellectual founder George Merrick now serves as a 157-room hotel and hosts a mix of offices and retail space.

According to DeCubas, the clinic will make pain management, anti-aging and aesthetic regenerative medicine treatments readily available to physicians and patients in a clinical setting.

We could not be more pleased or gratified to announce this new shared path of medical and scientific promise with Dr. Mahl and the Coral Gables Community, DeCubas says.

This opens new possibilities for discovery and treatments, and we are proud to work alongside Dr. Mahl to grow Regenestem Health into a cornerstone of patient care that will serve the community for years to come.

View original post here:
Regenestem Network and Charles Mahl, M.D. Launch Regenestem Miami in Westin Colonnade

Dr. Curt Civin Discussing Regenerative Medicine
Tune in to find out about the next revolution in medicine and how it can change your life. Featuring Curt Civin, Director of the Center for Stem Cell Biology and Regenerative Medicine. Assistant...

By: Next Healthcare Inc.

Follow this link:
Dr. Curt Civin Discussing Regenerative Medicine - Video

Dental education: The Department of Orthodontics, Yenepoya Dental College, and Yenepoya Research Centre, Yenepoya University, organised a continued dental education programme on Perspective in regenerative medicine recently.

Adoor Amanulla, Paediatric Oncologist at the Beaumont Health System, Beaumont, Michigan, U.S., inaugurated it. In his address Dr. Amanulla highlighted the revolutionary developments in bone marrow transplantation in treating many diseases. Vice-Chancellor of the university P. Chandramohan, in his presidential address, stressed the importance of stem cell therapy in the treatment of diabetic retinopathy and glaucoma. He spoke about the upcoming applications of cell-based therapy. Akhter Husain, Head, Department of Orthodontics, spoke on the significance and scope of regenerative medicine in India.

In the technical session, M. Rahmatulla, founder President, Indian Society for Dental Research, spoke on the role of regenerative medicine in restorative treatment of tissue damage. He explained the potential of stem cell therapy in autoimmune diseases, cancer and diabetes. He emphasised the need to introduce academic courses in regenerative medicine.

S. Sankaranarayana, Director of Mother Cell Regenerative Centre, Tiruchirapalli, Tamil Nadu, a pioneer in designing the therapeutic regimen for diabetic foot ulcer using dental pulp stem cells, highlighted the recent achievements in cell-based therapy in dentistry and medicine. He emphasised the osteogenic potential of dental pulp stem cells in the treatment of osteoradionecrosis.

Bipasha Bose, Assistant Professor, Yenepoya Research Centre, spoke on pluripotent stem cells, their basic biology and applications in diabetes. Uppala Radhakrishna, Director of Epigenomics at the Beaumont Research Institute, U.S., spoke on the genetic/ epigenetic causes of various developmental disorders. He substantiated the significance of regenerative medicine in the treatment of cleft lip and palate.

B.H. Sripathi Rao, Dean, Dental College, was present.

Radiographers conference: The Karnataka Medical Radiographers and Allied Technologists Association organised its State-level two-day conference for 2015 at Father Muller Medical College recently.

Deputy Commissioner of Dakshina Kannada A.B. Ibrahim, who inaugurated it, said that medical professionals should win the confidence of patients by assuring quality, fair and ethical treatment. It would enhance the standing of the professionals in society.

Stating that radiology had made rapid strides in recent years he said that technologies have made accurate diagnosis possible.

Anand Venugopal, Medical Superintendent of Kasturba Medical College Hospitals, Mangaluru, said that medical technologists were in the first line of defence. Patient safety, empathy and quality control should be the hallmarks of professional commitment, he said.

Read the original:
Events in Dakshina Kannada

Portland, Oregon and Miami, Fla. (PRWEB) February 10, 2015

Global Stem Cells Group and the Regenerative Technology Alliance (RTA) have signed a memorandum of understanding to evaluate and promote stem cell training programs. RTA, a global provider of standards and certification for the emerging fields of regenerative medicine and science, will work with the Global Stem Cells Group to evaluate the regenerative medicine companys training programs and assess GSCGs participating physicians against the RTAs established international standards for the practice of regenerative and cell-based medicine.

Our new alliance with the RTA is a natural step toward establishing GSCGs recognition as a global leader in stem cell medicine, says Global Stem Cells Group CEO Benito Novas. This is a perfect fit for us, as Global Stem Cells Group shares the RTAs focus on high standards and transparency, especially when it comes to patient safety and advancing the field of stem cell medicine.

We are very pleased to have this alliance, says David Audley, General Secretary and Chair of the RTA. Our goal is to provide the highest level of transparency and oversight for the industry. Working with Global will allow us to have a direct and dramatic impact on physician training.

For more information, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call 305-224-1858.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products, and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators, and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About the RTA

The Regenerative Technology Alliance (RTA) a global provider of standards and certification for the emerging fields of regenerative medicine and science, is a 501(c)3 and is supported by donations from individuals, corporations and foundations to help advance its critical mission of bringing peer oversight and transparency to the field of cell-based and regenerative medicine.

For more information visit the RTA website, email david(at)regen-tech(dot)org, or call 503-446-5039.

See the rest here:
Global Stem Cells Group Announces Alliance with Regenerative Technology

Cell Therapy, which is based in the Welsh capital Cardiff, says the medicine has the potential to reduce scarring of the heart muscle caused by a heart attack or failure.

Chief executive Ajan Reginald, who was previously at Roche, said crowd funding was a quick way to raise money for final stage trials or commercial launches.

Loading article content

"It was very fast and very efficient," he said. "We have spent five per cent of our time on fundraising, which enables me to spend 95 per cent of my time on the business."

The company's founder Martin Evans shared the 2007 Nobel Prize for medicine for groundbreaking stem cell research.

Cell Therapy used website Crowdcube to raise nearly three times its original target from more than 300 investors.

Mr Reginald said the backers included investment bankers, hedge fund employees and scientists.

"Crowd funding allows investors to look in detail at a company in their own time," he said, adding that some 10,000 investors had seen the pitch.

The company plans to publish data from clinical trials of the drug, called Heartcel, next month, before final stage trials with a view to a launch in 2016.

Read more here:
Biotech firm Cell Therapy claims crowdfunding record with heart drug

Durham, NC (PRWEB) February 04, 2015

STEM CELLS Translational Medicine (SCTM) presented Marc H. Dahlke, M.D., Ph.D. its second annual STEM CELLS Translational Medicine Young Investigator Award. The award fosters advancements in the field of stem cells and regenerative medicine by honoring a young researcher who is principle author of an article published in SCTM over the course of a year that is deemed to have the most impact and to push the boundaries of novel and insightful research.

Dr. Dahlkes paper describes the discovery of a universal stem cell product that not only seems to increase the long-term survival of organ transplants in instances when the donor is not related to the recipient, but also retains that immunological privileged state when the organ is then transplanted into yet another unrelated recipient. The paper was published in the August 2013 issue of SCTM.

This excellent study by Dr. Dahlke and his co-authors demonstrate the potential for multipotent adult progenitor cells to serve as a universal cell product. Being able to reduce the level of immunosuppressant drugs post-transplant could have significant benefits to patients, said Anthony Atala, M.D., Editor-in-Chief of SCTM. This study represents a promising pathway for clinical immunotherapy, and I congratulate our Young Investigator Award winner on this important accomplishment.

Dr. Dahlke is a lecturer for experimental surgery at Regensburg University, Germany, and an attending surgeon at Regensburg University Medical Center. He received both his M.D. (in 2002) and his Ph.D. (2004) from Hannover Medical School, where he was enrolled in the program for molecular medicine. He went on to receive specialty training in surgery as a fellow at the University of Sydney (Australia) and at Memorial Sloan Kettering Cancer Center in New York (US).

Currently, his lab in Regensburg focuses on the immunobiology of mesenchymal stem cells and the use of stem cell products for clinical application in solid organ transplantation and other indications. His group publishes regularly in this field, and Dr. Dahlke is the principal investigator of the first phase I study applying a mesenchymal stem cell product to liver transplant recipients.

He also is the founder of the MiSOT network (http://www.misot.eu), which aims to bring together academic and commercial research with the goal of bringing mesenchymal stem cell therapies to the transplantation clinic. He also serves as a reviewer for numerous journals in the immunology field.

The STEM CELLS Translational Medicine Young Investigator Award, which includes a $10,000 cash incentive, is co-sponsored by CIRM and Quintiles in cooperation with the Regenerative Medicine Foundation. Its winner is selected each year by the journals editorial board, made up of leading experts in the field of regenerative medicine worldwide.

###

About STEM CELLS Translational Medicine: STEM CELLS TRANSLATIONAL MEDICINE (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

Original post:
Paper Describing Universal Stem Cell Product Earns Author the 2014 SCTM Young Investigator Award